Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001570562-18-000027
Filing Date
2018-05-08
Accepted
2018-05-08 21:15:23
Documents
3
Period of Report
2018-05-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_152582846315584.html 3  
1 FORM 3 wf-form3_152582846315584.xml 3 1765
2 POA-MOATAZEDI form3exhibit241poamoataz.htm EX-24 3830
3 POA-MOATAZEDI (GRAPHIC) form3exhibit241poamoataz001.jpg GRAPHIC 193754
  Complete submission text file 0001570562-18-000027.txt   274001
Mailing Address 17901 VON KARMAN AVENUE, SUITE 150 IRVINE CA 92614
Business Address 17901 VON KARMAN AVENUE, SUITE 150 IRVINE CA 92614 (949) 284-4555
Evolus, Inc. (Issuer) CIK: 0001570562 (see all company filings)

EIN.: 461385614 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O OBALON THERAPEUTICS, INC. 5421 AVENIDA ENCINAS, SUITE F CARLSBAD CA 92008
Business Address
MOATAZEDI DAVID (Reporting) CIK: 0001700836 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38381 | Film No.: 18816439